|
|
painreliefmedication
All symptoms reported were classified, taking into pain relief account information provided by patients on their concomitant drugs and diseases. male balding buying propecia To develop a systematic generic method of enabling patients to report symptoms which they believe to be due to a particular prescribed drug. A methodological study.AIMS. Lick pain imaginable). A proposed equianalgesic conversion ratio between 70:1 and 100:1 from oral slow-release morphine to transdermal fentanyl can be confirmed pain relief by our data. The use of transdermal fentanyl is gaining in importance in the management of cancer comfortlessness. Opioid therapy was no prescription needed pharmacies switched to transdermal fentanyl during in-patient treatment for 53 patients and during out-patient tramadol treatment for 11 patients. Switching opioids to transdermal fentanyl in a clinical settingINTRODUCTION.
Most symptoms (71.0%) were classified as being probably or possibly related to the drugs studied. Patients azythromycin discount pharmacy reporting large army of symptoms were more likely to report some which were classed as unlikely to be an ADR carisoprodol or unattributable (chi2 80.587, d.f. A piloted body system-based questionnaire was distributed to patients registered with 79 medical practices in Grampian prescribed one of nine recently marketed 'black triangle' drugs.
A component of medical records was plan-b examined to compare symptoms recorded with those reported by patients. Pain intensities were assessed on a numeric rating scale (NRS 0. The method could help to identify problems which patients perceive as being related to their drug therapy and contribute to increased ADR reporting.. The median per patient was 6.0 (range 0--71), with almost half (406, 48.5%) reporting fewer estradiol than five symptoms. Before conversion patients were treated with slow-release morphine (48%), immediate-release morphine (17%), buprenorphine (11%), tramadol (11%), levomethadone (5%), tilidine/naloxone (5%) and piritramid (3%). Respondents were clearly willing to report symptoms, the majority of which were classed as possibly/probably related to the drugs studied.
Thirty-six patients had antidepressants been treated with transdermal fentanyl before admission to our pain clinic, and relevant information was missing for one patient, so 64 patients were evaluated. These comprised four antidepressants, three antiepileptics and two analgesics. The opioid frond resulted in more pain relief or fewer side effects in half of the plan-b patients. We describe the reasons for switching opioid medication to transdermal fentanyl in a pain management unit.
Conversion rates from other opioids to transdermal fentanyl are suggested. Of the 742 reporting symptoms in questionnaires, 402 (54.2%) claimed to have reported some or all of these to their doctor. Byrom records of patients treated with transdermal fentanyl in our pain clinic were evaluated retrospectively. Responses from patients prescribed antidepressant drugs were more likely to include symptoms potentially caused by these drugs (74.5% of all symptoms reported) than those from patients prescribed analgesics (67.4%) or antiepileptics (65.1%, chi2 23.858, d.f. In 12 of 21 patients, in whom the medication was switched because of inadequate pain relief, a reduction in pain intensity was reported. Only 162 (22.6%) of 716 patient-reported symptoms were documented in the primary care medical records of 103 patients prescribed Tramadol ( Generic Ultram ) or venlafaxine. The results suggest that patients do not report all symptoms they suspect to be ADRs to their GP and that GPs do not record all symptoms which may be reported to them. A classification system was developed for the study to enable the assessment of symptoms reported for their potential relationship to patients' drug therapy.
Reduction of side effects was reported by 10 of 19 patients. A specialist pharmacist independently re-classified a sample of the symptoms to validate the process. A 36.3% response rate was obtained (837/2307) with 742 respondents (88.6%) reporting at least one symptom. From October 1995 to December 1997 101 patients received transdermal fentanyl.
Conversion ratios were calculated from the opioid dosage before and after conversion. Conversion to transdermal therapy may readjust the balance between opioid analgesia and side effects. Patient reporting of potential adverse drug reactions. Reasons for opioid rotation were inadequate pain relief ( 33%), the patients' wish to reduce oral medication (20%), gastrointestinal side effects such as nausea (31%), car sickness (13%) and constipation (19%), dysphagia (27%) or others.
This requested respondents to identify any symptoms experienced over the previous year which they thought could be due to the 'black triangle' drug they had used. Agreement between researcher and specialist on the classification of 75.3% of 716 symptoms was obtained (Kappa 0.563).
.
|
|
